In this issue of Pro Te (Volume 11, No.3), we examine three important topics that are sure to capture your interest.
The Supreme Court’s Bristol-Meyers Squibb decision was met with no small amount of (completely justified)...more
12/5/2018
/ Actual Damages ,
Advertising ,
Bristol-Myers Squibb ,
Bristol-Myers Squibb Co v Superior Court of California - San Francisco County ,
Cosmetics ,
Damage Caps ,
FDA Approval ,
Personal Jurisdiction ,
Pharmaceutical Industry ,
Product Labels ,
Wrongful Death
It’s hard to believe a decade has passed since we delivered our first edition of Pro Te: Solutio to your door. Those years have brought enormous changes in the world and in our industry. Innovation has driven everything we...more
7/17/2018
/ 21st Century Cures Act ,
Affordable Care Act ,
Client Services ,
Depositions ,
DQSA ,
Emergency Response ,
Enforcement Actions ,
FDASIA ,
Food and Drug Administration (FDA) ,
Food and Drug Administration Amendments Act (FDAAA) ,
Health Care Providers ,
Health Insurance ,
Hospitals ,
Innovation ,
Juror ,
Jury Trial ,
Law Firm Associates ,
Law Firm Ownership ,
Law Firm Partners ,
Law Practice Management ,
Manufacturers ,
Medical Device User Fee Program (MDUFA IV) ,
Medical Devices ,
Multidistrict Litigation ,
Patient Rights ,
Patient Safety ,
Patients ,
Pharmaceutical Industry ,
Preemption ,
Questionnaires ,
Reporting Requirements ,
State Law Tort Claims ,
Voir Dire ,
Witness Preparation
In This Issue:
- Can Experts Testify as to the Ethics or State of Mind of Corporate Defendants?
- Patent Reform for Biotech Companies
- United States v. Caronia and its Implications for Off-Label...more
5/22/2013
/ America Invents Act ,
Biotechnology ,
Daubert Standards ,
Ethics ,
Expert Testimony ,
Federal Food Drug and Cosmetic Act (FFDCA) ,
First-to-File ,
Food and Drug Administration (FDA) ,
Free Speech ,
Off-Label Use ,
Patent Reform ,
Patents ,
Pharmaceutical Industry ,
Prior Use ,
Testimony